Definium Therapeutics, Inc. — Income Charts
3 years of history · ending 2023-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$5M
R&D
$52M
D&A
$3M
Operating Income
$-94M
EBITDA
$-91M
Interest Expense
$920K
Other Income/Expense
$-946K
Pretax Income
$-96M
Tax Provision
$-1M
Net Income
$-96M
Operating Margin
-2012.6%
Net Margin
-2052.6%
Effective Tax Rate
1.2%
Deferred Tax Assets
$114K
Deferred Tax Liabilities
$10K
DTA Valuation Allowance
$51M
NOL Carryforwards
$32M
ETR (Continuing Operations)
—
ETR Federal Statutory
21.0%
ETR State + Local (pp)
—
Revenue YoY Variation
212.0%
Income YoY Variation
-41.5%